BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Asset Impairment Charges	$ 2.2	$ 1.2
Revenues	3,777.9	3,899.6
Contract with Customer, Liability	586.7		$ 582.1
Amortization of Deferred Sales Commissions	$ 8.4	$ 7.2
Percent of Revenue Contributed	100.00%	100.00%
Provision for income taxes	$ 64.5	$ 148.0
Net earnings	213.3	492.1
Net Income (Loss) Attributable to Parent	212.9	491.6
Stockholders' Equity Attributable to Parent	10,341.5	10,721.1	10,096.6	$ 10,273.4
Capitalized Contract Cost, Amortization	2.4	3.1
Deferred Revenue, Revenue Recognized	165.3	163.8
Revenue, Remaining Performance Obligation, Amount	4,720.0
Contract with Customer, Performance Obligation Satisfied in Previous Period	10.4	31.7
Cash and cash equivalents	393.9		430.0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 393.9	$ 1,233.5	430.0	1,472.7
Ownership percentage below which investments are generally accounted for on the cost method (in thousandths)	20.00%
LabCorp Diagnostics [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percent of Revenue Contributed	63.00%	63.00%
Retained Earnings [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Net Income (Loss) Attributable to Parent	$ 212.9	$ 491.6
Stockholders' Equity Attributable to Parent	$ 10,729.9	$ 10,948.4	$ 10,581.7	$ 10,456.8